SCHEMBL4058728

SCHEMBL4058728

Fc1ccc(/C=C/c2nc3cc(Br)ccc3o2)c(F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 5/20 0.43
PTGS1 P23219 1/20 0.37
PTGS2 P35354 1/20 0.37
HPSE Q9Y251 2/20 0.36
SNCA P37840 1/20 0.35
KDM4E B2RXH2 3/20 0.34
MEN1 O00255 2/20 0.34
NPC1 O15118 2/20 0.34
ALDH1A1 P00352 2/20 0.34
HPGD P15428 2/20 0.34
RAB9A P51151 2/20 0.34
KMT2A Q03164 2/20 0.34
CYP2D6 P10635 1/20 0.34
HTR2A P28223 3/20 0.34
KCNH2 Q12809 3/20 0.34
HTR2C P28335 2/20 0.34
XDH P47989 1/20 0.33
MAPT P10636 1/20 0.33
HTT P42858 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4058735 1.00 NFE2L2 (0.43) NFE2L2PTGS1PTGS2HPSESNCA
SCHEMBL4057657 0.90 NFE2L2 (0.44) NFE2L2PTGS1PTGS2SNCAKDM4E
SCHEMBL4057664 0.90 NFE2L2 (0.44) NFE2L2PTGS1PTGS2SNCAKDM4E
SCHEMBL4062514 0.86 NFE2L2 (0.43) NFE2L2KDM4EMEN1NPC1ALDH1A1
SCHEMBL4062510 0.86 NFE2L2 (0.43) NFE2L2KDM4EMEN1NPC1ALDH1A1
SCHEMBL23064075 0.82 NFE2L2 (0.54) NFE2L2PTGS1PTGS2SNCAKDM4E
SCHEMBL26327019 0.82 NFE2L2 (0.54) NFE2L2PTGS1PTGS2SNCAKDM4E
SCHEMBL4061770 0.81 MEN1 (0.51) NFE2L2HPSEKDM4EMEN1NPC1
SCHEMBL4061775 0.81 MEN1 (0.51) NFE2L2HPSEKDM4EMEN1NPC1
SCHEMBL4055103 0.80 NFE2L2 (0.47) NFE2L2PTGS1PTGS2KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B NFE2L2 996/4885PTGS1 1843/4885PTGS2 2171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.